Future Directions

Our generics business will continue to utilize our core competency in drug delivery expertise and formulation development to target high-value solid oral and alternative dosage form (ADF) ANDAs that are difficult to develop and that bring sustainable profitability. This includes products with the potential for six months of exclusivity for being first-to-file or products that are difficult to develop. Externally, we are looking at opportunities to acquire products, technologies or companies with strategic value mainly in the alternative dosage area, such as injectables, creams and ointments, inhalers or patches.


In the specialty pharma market, we are focused on internally developing Central Nervous System (CNS) disorder products where we can deliver meaningful patient benefits and develop strong intellectual property positions. We believe the successful development of our brand business is critical to our future growth as brand products provide longer product life cycles with the potential for higher profits. Our strategic initiatives for growth include continuing our internal R&D focus on neurology by building a strong pipeline. In addition, we are searching for external growth opportunities through partnerships and M&A in CNS.